T2DM and CV Outcomes Trials: A Deep Dive!

Completed DPP-4 Inhibitor CV Outcomes Trials in T2DM

SAVOR-TIMI 53: Study Design

December 2008 FDA Guidance on Evaluating CV Risk in New Antidiabetic Therapies for T2DM

SAVOR-TIMI 53: Primary Endpoint

SAVOR-TIMI 53: Hospitalization for HF

EXAMINE: Study Design

EXAMINE: Primary Endpoint

EXAMINE: Hospitalization for HF

TECOS: Study Design

TECOS: Effect of Sitagliptin vs Placebo on CV Outcomes in T2DM

TECOS: Hospitalization for HF

Future DPP-4 CV Outcomes Trials in T2DM

ELIXA: Study Design

EMPA-REG OUTCOME: Study Design

EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on the Primary Composite Outcome

EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on CV Death

EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on Individual CV Endpoints

EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on All-cause Mortality

EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on HF Hospitalization

EMPA-REG OUTCOME: CV Death in Subgroups of Patients

EMPA-REG OUTCOME: HF Hospitalization in Patients With vs Without HF at Baseline

Ongoing SGLT2 Inhibitor CV Outcomes Trials

ADA/EASD Position Statement: Antihyperglycemic Therapy in T2DM

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)